Clinical trials: Acid Regurgitation
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.
To describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using GERD Impact Scale questionnaire (GIS) by total GERD patient population and by treatment…
- Trial name
- NCT00786773
- Where
- 18 sites in Vietnam
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Heartburn
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton…
- Conditions
- Gastroesophageal Reflux Disease, Heartburn, Regurgitation
- Trial name
- NCT01005251
- Testing
- lesogaberan (AZD3355)
- Where
- United States
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Erosive Reflux Disease, Heartburn
Observationa Study is a Prospective and Multi-institutional Observational Study.
This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the…
- Conditions
- Erosive Reflux Disease, Heartburn, Acid Regurgitation
- Trial name
- NCT06952855
- Where
- South Korea
- Volunteers
- 5,536 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Heartburn, Upper Abdominal Pain
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2…
- Conditions
- Heartburn, Upper Abdominal Pain, Nausea, Acid Regurgitation
- Trial name
- NCT00625274
- Testing
- Esomeprazole, Lansoprazole, Pantoprazole
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD), Heartburn
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
- Trial name
- NCT01129713
- Testing
- Secretol, Nexium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Effexus Pharmaceutical
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
The EndoGastric Solutions TEMPO Trial
The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal…
- Trial name
- TEMPO (NCT01647958)
- Testing
- EsophyX System with SerosaFuse fasteners, PPI
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- EndoGastric Solutions
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca